Pacira Biosciences (PCRX) Patent Misrepresentation Case

The defendant has requested the court to dismiss the case.

D. New Jersey

Court

2:25-cv-00322

Case number

08/02/2023

Class period Start

08/08/2024

Class period End

03/14/2025

Lead Plaintiff motion deadline

$PCRX investors filed a lawsuit against Pacira Biosciences for misleading shareholders about  Exparel's patent strength and protection against generics.
On August 9, 2024, Pacira announced that the U.S. District Court invalidated its key Exparel patent, following this news, $PCRX stock dropped by 47.7%.
$PCRX investors can join this case to be notified about potential recovery.
Case Details:

Between August 2, 2023, and August 8, 2024, Pacira assured investors that Exparel’s patents were strong and would protect the drug from generic competitors.

The company highlighted Exparel as its flagship product, accounting for 80% of Pacira’s revenue, and emphasized its plans for expanded usage and production.

However, on August 9, 2024, Pacira announced that its key Exparel patent had been invalidated, raising concerns about the strength of its other patents and the risk of generic competition.

Following the announcement, PCRX dropped by 47.7%.

Based on these events, $PCRX investors filed a lawsuit against Pacira Biosciences, claiming the company:
It misled investors about the strength of Exparel’s patent protection and its ability to block generic competition.
It overstated its ability to expand Exparel’s market dominance despite legal risks.
Investors believe Pacira misrepresented Exparel’s patent security and the associated risks, leading to significant financial losses when the patent was invalidated.

Case Type

US Securities Class Action

Case Status

Motion to dismiss

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

08/09/2024

Filing date

01/13/2025

Lead Plaintiff Deadline

03/14/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.